| pathology | treatment | patient | Demonstrated benefit and harm | k | | | |
|---|
| thrombosis prevention | aspirin | not classified | versus control No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Gelfer, 2006 | CECT + aspirin vs LMWH | | | | | Lieberman (A), 1994 | IPC + aspirin vs aspirin | | | DVT 0.81 [0.31; 2.11] | | Hull (+asp), 1979 | IPC + aspirin vs aspirin | | | DVT 0.27 [0.03; 2.11] | | Hull 2 (+asp), 1979 | IPC + aspirin vs aspirin | | | |
| Trial | Treatments | Patients | Method |
|---|
| Gelfer, 2006 | continuous enhanced circulation therapy (CECT) combined with low-dose aspirin (n=-9) vs. enoxaparin 40 mg daily (n=-9) | patients who underwent total hip or knee arthroplasty | open Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: 8 days | | Lieberman (A), 1994 | hypotensive epidural anesthesia, external pneumatic-compression boots, and aspirin (n=130) vs. hypotensive epidural anesthesia and aspirin (n=130) | primary unilateral or bilateral total hip arthroplasty with use of hypotensive epidural anesthesia | open Parallel groups Sample size: 130/130 Primary endpoint: FU duration: | | Hull (+asp), 1979 | (n=-9) vs. (n=-9) | patients undergoing elective knee surgery | open Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: | | Hull 2 (+asp), 1979 | (n=-9) vs. (n=-9) | patients undergoing elective knee surgery | open Sample size: -9/-9 Primary endpoint: FU duration: |
|
| thrombosis prevention | UFH | not classified | versus control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Siragusa (H), 1994 | IPC + UFH vs UFH | | | DVT 0.60 [0.24; 1.47] PE NaN [NaN; NaN] | | Killewich, 1997 | IPC + UFH vs control | | | DVT 0.40 [0.04; 4.25] | | Ramos, 1996 | IPC + UFH vs UFH | PE 0.42 [0.25; 0.69] | | |
| Trial | Treatments | Patients | Method |
|---|
| Siragusa (H), 1994 | (n=35) vs. (n=35) | | open Parallel groups Sample size: 35/35 Primary endpoint: FU duration: | | Killewich, 1997 | low-dose heparin sodium therapy (5000 U every 12 hours) and calf-length intermittent mechanical compression devices (n=-9) vs. no prophylaxis (n=-9) | patients undergoing aortic reconstruction for aneurysmal or occlusive disease | open Sample size: -9/-9 Primary endpoint: FU duration: | | Ramos, 1996 | prophylactic regimen of Pneumatic compression stocking and subcutaneous heparin (n=1355) vs. with 5,000 U of subcutaneous heparin every 12 h (n=1196) | cardiac surgery | open Parallel groups Sample size: 1355/1196 Primary endpoint: FU duration: |
|
| thrombosis prevention | UFH | not classified | versus heparin No demonstrated result for efficacy | 4 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Wille-Jorgensen, 1991 | GCS + UFH vs UFH | DVT (asymptomatic or symptomatic) 0.17 [0.04; 0.72] | | PE 0.00 [0.00; NaN] | | Wille-Jorgensen, 1985 | GCS + UFH vs UFH | DVT (asymptomatic or symptomatic) 0.19 [0.04; 0.83] | | | | *Rasmussen (adj), 1988 | GCS + UFH vs UFH | | | DVT (asymptomatic or symptomatic) 0.88 [0.54; 1.42] | | Torngren, 1980 | GCS + UFH vs UFH | DVT (asymptomatic or symptomatic) 0.33 [0.11; 0.99] | | |
| Trial | Treatments | Patients | Method |
|---|
| Wille-Jorgensen, 1991 | low dose heparin and graded compression stockings (n=83) vs. low dose heparin (n=83) | patients undergoing Abdominal surgery | parallel groups Sample size: 83/83 Primary endpoint: FU duration: | | Wille-Jorgensen, 1985 | low-dose heparin treatment with graded compression stockings (n=86) vs. low-dose heparin treatment (5000 units twice daily subcutaneously) (n=90) | patients undergoing Abdominal surgery | parallel groups Sample size: 86/90 Primary endpoint: FU duration: | | *Rasmussen (adj), 1988 | subcutaneous heparin and graduated compression stockings to the knee (TED stockings), (n=-9) vs. subcutaneous heparin (n=-9) | patients (age more than 40 yrs) admitted for major abdominal surgery | open Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: | | Torngren, 1980 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: |
|
